Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report released on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

A number of other equities research analysts have also issued reports on APTO. Canaccord Genuity Group decreased their target price on shares of Aptose Biosciences from $15.00 to $6.00 and set a buy rating for the company in a research note on Thursday, May 16th. HC Wainwright restated a buy rating and set a $23.00 price target on shares of Aptose Biosciences in a report on Wednesday, March 27th. Finally, Piper Sandler reissued an overweight rating and set a $5.00 price objective on shares of Aptose Biosciences in a research report on Wednesday, April 3rd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of Moderate Buy and an average target price of $14.83.

Aptose Biosciences Stock Performance

Aptose Biosciences stock opened at $0.87 on Friday. Aptose Biosciences has a twelve month low of $0.85 and a twelve month high of $5.86. The firm has a market cap of $15.81 million, a PE ratio of -0.14 and a beta of 1.39. The firm’s 50 day moving average price is $1.15 and its two-hundred day moving average price is $1.71.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.09. Equities analysts anticipate that Aptose Biosciences will post -2.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc bought a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned about 0.16% of Aptose Biosciences as of its most recent SEC filing. Hedge funds and other institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.